Keros Therapeutics, Inc.
KROS | US
Overview
Corporate Details
- ISIN(s):
- US4923271013
- LEI:
- Country:
- United States of America
- Address:
- 1050 WALTHAM STREET, SUITE 302, 2421 LEXINGTON
- Website:
- https://www.kerostx.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Keros Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Keros Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Keros Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan
4564
Japan
4564
Biotech for animal health and xenotransplantation using genetically engineered pig organs.
South Korea
153710
South Korea
153710
Biotech developing intranasal drugs for concussion and other brain disorders.
United States of America
OGEN
United States of America
OGEN
South Korea
476040
Developing degrader-antibody conjugates for cell-selective protein degradation to treat cancer.
South Korea
475830
South Korea
475830
Acquires biopharma R&D platforms to build a diverse portfolio of healthcare therapies.
United States of America
OSRH
United States of America
OSRH
Developing a cancer vaccine to treat HER2-expressing tumors, primarily Osteosarcoma.
United States of America
OSTX
United States of America
OSTX
Develops precision blood tests using 3D genomics for cancer diagnosis and therapy guidance.
United Kingdom
OBD
United Kingdom
OBD
Acquires European pharmaceutical subcontractors to build an integrated healthcare services group.
Belgium
OXUR
Belgium
OXUR
Developing innovative therapeutics for CNS disorders (ALS, MS) and RASopathies.
United States of America
KTTA
United States of America
KTTA